| Literature DB >> 21779348 |
Jorge S Burns1, Malthe Kristiansen, Lars P Kristensen, Kenneth H Larsen, Maria O Nielsen, Helle Christiansen, Jan Nehlin, Jens S Andersen, Moustapha Kassem.
Abstract
BACKGROUND: Acquisition of a blood supply is fundamental for extensive tumor growth. We recently described vascular heterogeneity in tumours derived from cell clones of a human mesenchymal stem cell (hMSC) strain (hMSC-TERT20) immortalized by retroviral vector mediated human telomerase (hTERT) gene expression. Histological analysis showed that cells of the most vascularized tumorigenic clone, -BD11 had a pericyte-like alpha smooth muscle actin (ASMA+) and CD146+ positive phenotype. Upon serum withdrawal in culture, -BD11 cells formed cord-like structures mimicking capillary morphogenesis. In contrast, cells of the poorly tumorigenic clone, -BC8 did not stain for ASMA, tumours were less vascularized and serum withdrawal in culture led to cell death. By exploring the heterogeneity in hMSC-TERT20 clones we aimed to understand molecular mechanisms by which mesenchymal stem cells may promote neovascularization. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2011 PMID: 21779348 PMCID: PMC3133605 DOI: 10.1371/journal.pone.0021888
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Cord formation of primary hMSC and hMSC-TERT clones.
Cord morphogenesis with cell sprouting in A: Primary hMSC, B: -BC8 and C: -BD11 induced by culture on Matrigel® overnight. D,E,F: Phase contrast photomicrographs of -BC8 and G,H,I: -BD11 cells during serum starvation. D,G: confluent cells before serum starvation for E,H: 2 days and F,I: 7 days. J, Growth curves for -BC8 (□) and -BD11 (•) in serum free medium, *p<0.05. K: -BD11 cells after 72 hours in serum free medium, showing early cell sprouts (S) and a lamellipodium terminating in a focal contact point (FCP) within the lacuna. L: RT-PCR analysis of cDNA obtained from serum-starved hMSC-TERT20 clones (time without serum indicated in hours). M,N,O: Independent examples of plastic adherent primary hMSCs spontaneously forming cords when depleted of growth factors for 2 weeks.
Figure 2Matrigel encapsulated sponge angiogenesis assay (MESA).
Consecutive 4 µm histological sections from matrigel plugs isolated after 7 days in vivo. A,B: Anti-FITC antibody visualized by brown chromogen diaminobenzidine, detected the blood pooling agent FITC-Dextran, indicating anastomosis with host circulation. A: Sponge region with -BD11 cells. B: Sponge region with -BC8 cells. C,D: Human specific anti-CD99 was used to confirm presence of C: -BD11 and D: -BC8 cells. E: Murine specific anti-CD34 stain of the sponge region with -BD11 cells. F: A parallel section stained with human specific anti-CD31. G–J: Laser scanning confocal microscopy of 4 µm histological sections of plugs seeded with -BD11 cells 63× magnification. G: α-smooth muscle actin stain visualized with goat anti mouse IgG2b Alexa 488 (green); H: TRA-1-85 stain visualized with goat anti mouse IgG1 Alexa 555 (red); I: DAPI stain of nuclei (blue); J: G–I overlay. N.B. red blood cells have red and green spectrum autofluorescence and appear orange. No cells double-stained for α-smooth muscle actin and TRA-1-85. Scale bar, A–F: 100 µm; G–J: 10 µm.
Figure 3Analysis of hMSC-TERT-BC8 and -BD11 extracellular matrix (ECM).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis of equivalent total protein extracts of decellularized cells. A: Silver stained -BC8 proteins (left lane) and -BD11 proteins (right lane). Phase contrast photomicrographs of TIME endothelial cells seeded on decellularized matrix derived from B,C: -BC8 and D,E -BD11 clones on plastic dishes after B,D: 1 day or C,E: 10 days after seeding. Tubular cord formation by TIME cells when seeded on decellularized -BD11 matrix. F: Phase contrast photomicrographs of TIME cells aligned along detached free-floating cords of decellularized matrix within 2 hours of seeding. G: At 21 days, stable endothelial cord structures were maintained. H–J: 3D reconstructed images of TIME cells from a 21 day old cord structure stained with a FITC labeled Ulex Europaeus agglutinin lectin I (green) and propidium iodine counterstained nuclei (red) obtained with confocal microscopy. H: A longitudinal view of the tubule at 63× magnification. Red lines indicate region corresponding to XZ sections in adjacent figures. I,J: XZ-section stacks were used for cross section 3D-reconstruction showing TIME cell tube-like organization. Scale bar, B–E: 100 µm; H–J: 10 µm.
Figure 4Histological sections of MESA plugs after 7 days in vivo.
A: Photomicrograph of a MESA implant showing a 1 cm diameter matrigel plug with a centrally implanted sponge (arrow, “S”). B: Haemotoxylin and Eosin stain of a sponge loaded with ECBM-MV2 medium. C,D: Histological sections stained with murine specific anti-CD34 antibody visualized by brown chromogen diaminobenzidine. C: Field of view of matrigel adjacent to sponge seeded with -BC8 cells. D: Field of view of matrigel adjacent to sponge seeded with -BD11 cells. E: Chalkley count quantification of vasculature adjacent to the Matrigel® embedded sponge. *P<0.05, Kruskal-Wallis. F,G: Histological sections showing migratory cells within the Matrigel® surrounding F, control medium sponges or G–I: sponges with -BD11 decellularized matrix, stained blue with Masson's trichrome. H,I: Anti-CD34 antibody was used to visualize endothelial cells (brown) in regions of the Matrigel® I: with or H: without decellularized matrix. Scale bar, 100 µm.
Angiogenic ECM/cell surface proteins in -BD11 decellularized matrix.
| Protein name | Accession number | Gene symbol | Cellular location | Evidence for role in angiogenesis [Reference] |
| Activated leukocyte cell adhesion molecule (CD166) | IPI00015102.2 | ALCAM | PM | Targeted Antibodies diminished endothelial capillary formation induced by Galectin-8 |
| Aminopeptidase N (CD13) | IPI00221224.6 | ANPEP | PM | Knockout mice show impaired angiogenesis |
| CD44 Antigen precursor | IPI00305064.1 | CD44 | PM | Mediates activity of antiangiogenic peptide |
| CD47 | IPI00413696.5 | CD47 | PM | Thrombospondin-1 receptor, antagonises nitric oxide |
| Enolase 1 | IPI00465248.5 | ENO1 | PM | A hypoxia-induced protein in endothelial cells |
| Epidermal Growth factor receptor | IPI00018274.1 | EGFR | PM | Important for angiogenic factor secretion by MSC |
| Glycoprotein non metastatic protein B | IPI00470529.3 | GPNMB | PM | Shed ectodomain enhances endothelial recruitment |
| Insulin Like Growth Factor 2 receptor | IPI00289819.4 | IGF2R | PM | Mediates endothelial progenitor cell homing |
| Integrin alpha-2 precursor | IPI00013744.1 | ITGA2 | PM | Mediates endothelial |
| Integrin alpha-3 precursor (CD49c) | IPI00290043.1 | ITGA3 | PM | Alpha3beta1 integrin mediated inter-cell crosstalk for endothelial migration |
| Integrin alpha-5 precursor | IPI00306604.5 | ITGA5 | PM | Targeting siRNA caused vessel shrinkage |
| Integrin alpha-6 precursor (CD49f) | IPI00010697.1 | ITGA6 | PM | Increased expression in angiogenic tumour vessels |
| Integrin alpha-V precursor (CD51) | IPI00027505.2 | ITGAV | PM | An anti-angiogenic target |
| Integrin beta 1 precursor | IPI00217563.3 | ITGB1 | PM | Gene inactivation via Cre-loxP in mice caused mural cell defects |
| Integrin beta 3 precursor | IPI00303283.2 | ITGB3 | PM | Antibody reduced adhesion of MSC to endothelium |
| Integrin beta 5 precursor | IPI00788112.1 | ITGB5 | PM | Overexpression enhanced angiogenic cell function |
| Metadherin | IPI00328715.4 | MTDH | PM | Mediates breast cancer cell adhesion to endothelium |
| Neuropilin 1 | IPI00398715.5 | NRP1 | PM | Receptor for angiogenic factors |
| Nucleolin | IPI00444262.3 | NCL | PM | Mediates cell migration and tubule formation in angiogenic vessels |
| Platelet-derived growth factor receptor beta precursor | IPI00015902.3 | PDGFRB | PM | Targeted antibodies prevented MSC tubule formation on matrigel |
| Pro low-density lipoprotein receptor related protein 1 precursor (CD91) | IPI00020557.1 | LRP1 | PM | Regulates ECM in blood vessel formation and stabilization |
| Semaphorin 7A | IPI00025257.1 | SEMA7A | PM | Binds integrins, promotes axon outgrowth |
| Talin-1 | IPI00298994.5 | TLN | PM | Maintains integrin complexes interacting with VCAM-1 |
| Tetraspanin | IPI00298851.4 | CD151 | PM | Complexes with integrins to enhance angiogenesis |
| Thy-1 cell surface antigen (CD90) | IPI00022892.2 | THY1 | PM | Cytomegalovirus induced down regulation led to vascular disease |
| Annexin A2 | IPI00455315.4 | ANXA2 | ECM | Interacts with pro-angiogenic S100A4 protein |
| Basigin (CD147) | IPI00795150.1 | BSG/EMMPRIN | ECM | Stimulates endothelial cell migration and tube formation |
| Cathepsin S | IPI00299150.4 | CTSS | ECM | Promotes pericellular hydrolysis and targeted antibodies inhibited angiogenesis |
| collagen, type VI, alpha 1 | IPI00291136.4 | COL6A1 | ECM | Associated with tumour stroma and matrix remodelling for microvasculature |
| collagen, type VI, alpha 2 precursor | IPI00304840.4 | COL6A2 | ECM | ibid |
| collagen, type VI, alpha 3 precursor | IPI00022200.2 | COL6A3 | ECM | ibid |
| Elastin microfibril interfacer 1 | IP100013079.1 | EMILIN1 | ECM | Knockout mice have vascular defects |
| Fibronectin 1 isoform4 preprotein | IPI00414283.5 | FN1 | ECM | Promotes brain endothelial cell survival and growth |
| Fibulin-1 | IPI00218803.2 | FBLN1 | ECM | Binds angiogenin, stabilizes new blood vessel walls |
| Galectin-1 | IPI00219219.3 | LGALS1 | ECM | Essential for tumor angiogenesis |
| Galectin-3 binding protein | IPI00023673.1 | LGALS3BP | ECM | Implicated as an angiogenic factor from gene expression data mining |
| Laminin B1 | IPI00853454.1 | LAMB1 | ECM | Increases endothelial sprout formation |
| Matrix Metalloproteinase-1 | IPI00008561.1 | MMP1 | ECM | Inducible by hypoxia in human bone marrow MSC |
| Matrix Metalloproteinase-3 | IPI00027782.1 | MMP3 | ECM | Upregulated by hypoxia in MSC |
| Matrix Metalloproteinase-14 | IPI00218398.5 | MMP14 | ECM | Plays a critical role in MSC-mediated sprouting |
| Perlecan | IPI00024284.4 | PLC | ECM | Impaired angiogenesis in Perlecan deficient mice |
| Tenascin C | IPI00220213.1 | TNC | ECM | Mediator of postnatal cardiac angiogenesis |
| Thrombospondin-1 | IPI00296099.6 | THBS1 | ECM | Negative modulator of angiogenesis, activates latent TGF-ß1 |
| Transforming growth factor beta induced | IPI00018219.1 | TGFBI | ECM | Mediates lymphatic endothelial cell adhesion to ECM in low oxygen |
| Transglutaminase 2 | IPI00218251.1 | TGM2 | ECM | Autoantibodies disturb angiogenesis |
| Versican isoform 1 | IPI00009802.1 | VCAN | ECM | Versican G3 domain promotes angiogenesis |
| High Mobility Group Box 1 | IPI00419258.4 | HMGB1 | S | An angiogenic switch molecule |
| HtrA1 Serine Peptidase 1 | IPI00003176.1 | HTRA1 | S | Mutated in single gene disorder of cerebral small vessels CARASIL |
| Lactadherin | IPI00002236.3 | MFGE8 | S | Binds integrins with a crucial role in VEGF-mediated neovascularization |
| Macrophage migrationinhibitory factor | IPI00293276.1 | MIF | S | Chemotactic for endothelial progenitor cells |
| Phosphoglycerate kinase I | IPI00169383.3 | PGK1 | S | Secretable glycolytic enzyme regulated by CXCR4 |
| Wingless type MMTV integration site member 5A | IPI00013178.5 | WNT5a | S | Regulates human endothelial cell proliferation and migration |
PM = Plasma Membrane, ECM = Extracellular Matrix, S = Secreted.
Figure 5Endothelial cell attachment to decellularized matrix ex vivo required -BD11 Galectin-1 expression.
A: RT-PCR analysis of LGALS1 gene expression in -BD11 cells grown in MEM with 10% FBS (day 0) versus serum starved cells treated with control siRNA (siControl) or anti-Galectin-1 siRNA (siLGALS1). B: Western blot of Galectin-1 protein expression in -BD11 cells grown in MEM with 10% FBS (day 0) versus cells serum starved for 3 days (clear bars). C: Western blot analysis of Galectin-1 protein in serum starved -BD11 cells 3 days after transfection with anti-LGALS1 siRNA (siLGALS-1) or control siRNA (siControl), versus routinely cultured TIME cells. D–G: Phase contrast photomicrograph of -BD11 cell monolayers grown D,E: with 10% FBS or F,G: without serum three days after treatment with D,F: control siRNA or E,G: anti-LGALS1 siRNA. H: Growth of -BD11 cells in 10% FBS (•,▴) or without FBS (○,▵) after transfection with control siRNA (○,•) or anti-LGALS1 siRNA (▵,▴). * p<0.05. I–L: Phase contrast photomicrograph of -BD11 decellularized matrix from 3 days serum-starved cultures of cells transfected with I,K: siControl or J,L: siLGALS1 I,J: before seeding with TIME endothelial cells and K,L: 30 minutes after seeding. M,P: ImageJ software rendition of endothelial cell distribution in 645.6 µm×433.5 µm fields used to determine spatial point coordinate data for endothelial cells seeded on matrix from -BD11 cells treated with M,: siControl or N,P: siGALS1. Ripley's K function graphs for Time endothelial cell distribution on decellularized matrix from -BD11 cells treated with O: siControl or P: siLGALS1. Q,R: Photomicrographs of Time cells 10 days after seeding on decellularized matrix from -BD11 cells treated with Q: siControl or R: siLGALS1. Scale bar, 100 µm.
Figure 6Endothelial cell association with -BD11 cells in vivo required matrix Galectin-1 expression.
A: RT-PCR analysis of LGALS1 gene expression in pooled populations of -BD11 cells transfected with shRNA lentiviral vectors targeting a scrambled sequence (Control shRNA) or Galectin-1 (LGALS1 shRNA). B–J: Histomorphology of -BD11 transfectant tumour sections immunohistochemically stained (brown) for B: Galectin-1 in cells transfected with control shRNA or C: Galectin-1 in cells transfected with LGALS1 shRNA. D: CD34 immunohistochemical staining targeted murine endothelial cells in a parallel serial section equivalent to C. E: Whole tumour section of -BD11 cells transfected with LGALS1 shRNA with neighbouring subregion immunohistochemically stained for CD34 (arrow). F–H: Higher power magnification of arrow region in E, stained for F: CD34, G: Human-specific CD99, H: Galectin-1. Higher power magnification of Galectin-1 staining in regions in H that were I: CD99+/CD34− and J: CD99+/CD34+. Scale bar, 100 µm.
Primers used for RT-PCR.
| Gene | Forward primer | Reverse primer | Annealing temp. (°C) | Amplicon size (bp) |
| Ang-1 |
|
| 60 | 70 |
| Ang-2 |
|
| 60 | 72 |
| Tie-1 |
|
| 60 | 68 |
| Tie-2 |
|
| 60 | 80 |
| CD105 |
|
| 60 | 188 |
| CD31 |
|
| 60 | 224 |
| VEGF-A |
|
| 55 | 62 |
| VEGFR-2 |
|
| 60 | 188 |
| LGalS1 |
|
| 60 | 250 |
| ß-actin |
|
| 60 | 430 |